Selected research
Industry Research
Valacyclovir Oral Industry Research Report 2026
Market perspective
The global Valacyclovir Oral market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Valacyclovir Oral is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Valacyclovir Oral is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Valacyclovir Oral is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Valacyclovir Oral include GSK, Teva, Sun Pharmaceutical, Shandong Luoxin Pharmaceutical Group, Sandoz, Mylan, Lunan Pharmaceutical, Zydus Pharmaceuticals and Wockhardt, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Valacyclovir Oral market in terms of revenue (US$ million) and, where applicable, sales volume (W Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/W Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Valacyclovir Oral Market by Company
GSK
Teva
Sun Pharmaceutical
Shandong Luoxin Pharmaceutical Group
Sandoz
Mylan
Lunan Pharmaceutical
Zydus Pharmaceuticals
Wockhardt
West-Ward Pharmaceuticals
Time Cap Labs
Tasly
Jubilant Pharma
Cipla
Aurobindo Pharma
Apotex
Valacyclovir Oral Segment by Type
1000mg Tablet
300mg Tablet
500mg Tablet
Others
Valacyclovir Oral Segment by Application
Hospital
Drug Store
Valacyclovir Oral Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Valacyclovir Oral market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Valacyclovir Oral and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Valacyclovir Oral.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Valacyclovir Oral manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Valacyclovir Oral by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Valacyclovir Oral in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 1000mg Tablet
- 300mg Tablet
- 500mg Tablet
- Others
Applications
- Hospital
- Drug Store
Companies covered
- GSK
- Teva
- Sun Pharmaceutical
- Shandong Luoxin Pharmaceutical Group
- Sandoz
- Mylan
- Lunan Pharmaceutical
- Zydus Pharmaceuticals
- Wockhardt
- West-Ward Pharmaceuticals
- Time Cap Labs
- Tasly
- Jubilant Pharma
- Cipla
- Aurobindo Pharma
- Apotex
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Valacyclovir Oral Market Size (2021-2032)
- 2.2.2 Global Valacyclovir Oral Sales (2021-2032)
- 2.2.3 Global Valacyclovir Oral Market Average Price (2021-2032)
- 2.3 Valacyclovir Oral by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 1000mg Tablet
- 2.3.3 300mg Tablet
- 2.3.4 500mg Tablet
- 2.3.5 Others
- 2.4 Valacyclovir Oral by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Drug Store
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Valacyclovir Oral Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Valacyclovir Oral Sales (W Units) of Manufacturers (2021-2026)
- 3.3 Global Valacyclovir Oral Revenue of Manufacturers (2021-2026)
- 3.4 Global Valacyclovir Oral Average Price by Manufacturers (2021-2026)
- 3.5 Global Valacyclovir Oral Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Valacyclovir Oral, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Valacyclovir Oral, Product Type & Application
- 3.8 Global Manufacturers of Valacyclovir Oral, Established Date
- 3.9 Global Valacyclovir Oral Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 GSK
- 4.1.1 GSK Company Information
- 4.1.2 GSK Business Overview
- 4.1.3 GSK Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 GSK Valacyclovir Oral Product Portfolio
- 4.1.5 GSK Recent Developments
- 4.2 Teva
- 4.2.1 Teva Company Information
- 4.2.2 Teva Business Overview
- 4.2.3 Teva Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Teva Valacyclovir Oral Product Portfolio
- 4.2.5 Teva Recent Developments
- 4.3 Sun Pharmaceutical
- 4.3.1 Sun Pharmaceutical Company Information
- 4.3.2 Sun Pharmaceutical Business Overview
- 4.3.3 Sun Pharmaceutical Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Sun Pharmaceutical Valacyclovir Oral Product Portfolio
- 4.3.5 Sun Pharmaceutical Recent Developments
- 4.4 Shandong Luoxin Pharmaceutical Group
- 4.4.1 Shandong Luoxin Pharmaceutical Group Company Information
- 4.4.2 Shandong Luoxin Pharmaceutical Group Business Overview
- 4.4.3 Shandong Luoxin Pharmaceutical Group Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Shandong Luoxin Pharmaceutical Group Valacyclovir Oral Product Portfolio
- 4.4.5 Shandong Luoxin Pharmaceutical Group Recent Developments
- 4.5 Sandoz
- 4.5.1 Sandoz Company Information
- 4.5.2 Sandoz Business Overview
- 4.5.3 Sandoz Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Sandoz Valacyclovir Oral Product Portfolio
- 4.5.5 Sandoz Recent Developments
- 4.6 Mylan
- 4.6.1 Mylan Company Information
- 4.6.2 Mylan Business Overview
- 4.6.3 Mylan Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Mylan Valacyclovir Oral Product Portfolio
- 4.6.5 Mylan Recent Developments
- 4.7 Lunan Pharmaceutical
- 4.7.1 Lunan Pharmaceutical Company Information
- 4.7.2 Lunan Pharmaceutical Business Overview
- 4.7.3 Lunan Pharmaceutical Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Lunan Pharmaceutical Valacyclovir Oral Product Portfolio
- 4.7.5 Lunan Pharmaceutical Recent Developments
- 4.8 Zydus Pharmaceuticals
- 4.8.1 Zydus Pharmaceuticals Company Information
- 4.8.2 Zydus Pharmaceuticals Business Overview
- 4.8.3 Zydus Pharmaceuticals Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Zydus Pharmaceuticals Valacyclovir Oral Product Portfolio
- 4.8.5 Zydus Pharmaceuticals Recent Developments
- 4.9 Wockhardt
- 4.9.1 Wockhardt Company Information
- 4.9.2 Wockhardt Business Overview
- 4.9.3 Wockhardt Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 Wockhardt Valacyclovir Oral Product Portfolio
- 4.9.5 Wockhardt Recent Developments
- 4.10 West-Ward Pharmaceuticals
- 4.10.1 West-Ward Pharmaceuticals Company Information
- 4.10.2 West-Ward Pharmaceuticals Business Overview
- 4.10.3 West-Ward Pharmaceuticals Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 West-Ward Pharmaceuticals Valacyclovir Oral Product Portfolio
- 4.10.5 West-Ward Pharmaceuticals Recent Developments
- 4.11 Time Cap Labs
- 4.11.1 Time Cap Labs Company Information
- 4.11.2 Time Cap Labs Business Overview
- 4.11.3 Time Cap Labs Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 Time Cap Labs Valacyclovir Oral Product Portfolio
- 4.11.5 Time Cap Labs Recent Developments
- 4.12 Tasly
- 4.12.1 Tasly Company Information
- 4.12.2 Tasly Business Overview
- 4.12.3 Tasly Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 Tasly Valacyclovir Oral Product Portfolio
- 4.12.5 Tasly Recent Developments
- 4.13 Jubilant Pharma
- 4.13.1 Jubilant Pharma Company Information
- 4.13.2 Jubilant Pharma Business Overview
- 4.13.3 Jubilant Pharma Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Jubilant Pharma Valacyclovir Oral Product Portfolio
- 4.13.5 Jubilant Pharma Recent Developments
- 4.14 Cipla
- 4.14.1 Cipla Company Information
- 4.14.2 Cipla Business Overview
- 4.14.3 Cipla Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Cipla Valacyclovir Oral Product Portfolio
- 4.14.5 Cipla Recent Developments
- 4.15 Aurobindo Pharma
- 4.15.1 Aurobindo Pharma Company Information
- 4.15.2 Aurobindo Pharma Business Overview
- 4.15.3 Aurobindo Pharma Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Aurobindo Pharma Valacyclovir Oral Product Portfolio
- 4.15.5 Aurobindo Pharma Recent Developments
- 4.16 Apotex
- 4.16.1 Apotex Company Information
- 4.16.2 Apotex Business Overview
- 4.16.3 Apotex Valacyclovir Oral Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Apotex Valacyclovir Oral Product Portfolio
- 4.16.5 Apotex Recent Developments
5 Global Valacyclovir Oral Market Scenario by Region
- 5.1 Global Valacyclovir Oral Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Valacyclovir Oral Sales by Region: 2021-2032
- 5.2.1 Global Valacyclovir Oral Sales by Region: 2021-2026
- 5.2.2 Global Valacyclovir Oral Sales by Region: 2027-2032
- 5.3 Global Valacyclovir Oral Revenue by Region: 2021-2032
- 5.3.1 Global Valacyclovir Oral Revenue by Region: 2021-2026
- 5.3.2 Global Valacyclovir Oral Revenue by Region: 2027-2032
- 5.4 North America Valacyclovir Oral Market Facts & Figures by Country
- 5.4.1 North America Valacyclovir Oral Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Valacyclovir Oral Sales by Country (2021-2032)
- 5.4.3 North America Valacyclovir Oral Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Valacyclovir Oral Market Facts & Figures by Country
- 5.5.1 Europe Valacyclovir Oral Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Valacyclovir Oral Sales by Country (2021-2032)
- 5.5.3 Europe Valacyclovir Oral Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Valacyclovir Oral Market Facts & Figures by Country
- 5.6.1 Asia Pacific Valacyclovir Oral Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Valacyclovir Oral Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Valacyclovir Oral Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Valacyclovir Oral Market Facts & Figures by Country
- 5.7.1 South America Valacyclovir Oral Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Valacyclovir Oral Sales by Country (2021-2032)
- 5.7.3 South America Valacyclovir Oral Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Valacyclovir Oral Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Valacyclovir Oral Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Valacyclovir Oral Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Valacyclovir Oral Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Valacyclovir Oral Sales by Type (2021-2032)
- 6.1.1 Global Valacyclovir Oral Sales by Type (2021-2032) & (W Units)
- 6.1.2 Global Valacyclovir Oral Sales Market Share by Type (2021-2032)
- 6.2 Global Valacyclovir Oral Revenue by Type (2021-2032)
- 6.2.1 Global Valacyclovir Oral Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Valacyclovir Oral Revenue Market Share by Type (2021-2032)
- 6.3 Global Valacyclovir Oral Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Valacyclovir Oral Sales by Application (2021-2032)
- 7.1.1 Global Valacyclovir Oral Sales by Application (2021-2032) & (W Units)
- 7.1.2 Global Valacyclovir Oral Sales Market Share by Application (2021-2032)
- 7.2 Global Valacyclovir Oral Revenue by Application (2021-2032)
- 7.2.1 Global Valacyclovir Oral Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Valacyclovir Oral Revenue Market Share by Application (2021-2032)
- 7.3 Global Valacyclovir Oral Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Valacyclovir Oral Value Chain Analysis
- 8.1.1 Valacyclovir Oral Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Valacyclovir Oral Production Mode & Process
- 8.2 Valacyclovir Oral Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Valacyclovir Oral Distributors
- 8.2.3 Valacyclovir Oral Customers
9 Global Valacyclovir Oral Analyzing Market Dynamics
- 9.1 Valacyclovir Oral Industry Trends
- 9.2 Valacyclovir Oral Industry Drivers
- 9.3 Valacyclovir Oral Industry Opportunities and Challenges
- 9.4 Valacyclovir Oral Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst